Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May;10(9):501.
doi: 10.21037/atm-22-621.

The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan-effectiveness, pitfalls and promises

Emanuela Guerra  1   2 , Saverio Alberti  1   3
Affiliations
Editorial

The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan-effectiveness, pitfalls and promises

Emanuela Guerra et al. Ann Transl Med. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-621/coif). EG is an inventor in patents WO201687651 and WO201784763, and a partner in Mediterranea Theranostic Srl. SA is an inventor in patents WO201089782, WO201687651 and WO201784763, and is the founder and CEO of Oncoxx Biotech Srl and Mediterranea Theranostic Srl.

Comment on

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
    Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.

References

    1. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecanhziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med 2019;380:741-51. 10.1056/NEJMoa1814213 - DOI - PubMed
    1. Thomas A, Pommier Y. Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res 2019;25:6581-9. 10.1158/1078-0432.CCR-19-1089 - DOI - PMC - PubMed
    1. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021;384:1529-41. 10.1056/NEJMoa2028485 - DOI - PubMed
    1. Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 2013;32:222-33. 10.1038/onc.2012.36 - DOI - PubMed
    1. Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol 2021;32:1148-56. 10.1016/j.annonc.2021.06.002 - DOI - PubMed